Loading company…
Virtu Pharmako develops biopharmaceuticals, including GLP-1 analogs, insulin products and recombinant enzymes.
Virtu Pharmako develops and produces biopharmaceuticals, including GLP-1 analogs, insulin products and recombinant enzymes for conditions such as metabolic diseases and cancer. Founded in 2021, the company is based in Jiaxing, China, and has a branch office in America. In October 2024, it closed a Series A funding round from Yongkan Investment, part of a larger CNY 250 million Series A round.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in